Uceris (Budesonide) Patent Expiration, LOE Window & CMS Spending
Uceris (Budesonide) by Bausch Health: FDA Orange Book LOE 2031-09-07, 2 AB generics, $2.2M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bausch Health |
| FDA Application & Pathway | N203634 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2031-09-07 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $2.2M |
| 2024 Medicare Part D Spend | $1.0M |
| 2024 Medicaid Spend | $1.2M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 22.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.
- Predicate Ledger FDA 510(k)Bausch Health / Bausch + Lomb FDA 510(k) & Recall Cohortdevices.meruai.co →
- Protocol Ledger NIH ClinicalTrials.govBausch Health / Bausch + Lomb Clinical Trials & Approvalstrials.meruai.co →
- ERISA Ledger DOL Form 5500Bausch Health / Bausch + Lomb 401(k) & Form 5500 Planerisa.meruai.co →